NL301212I2 - Lenacapavir of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder lenacapavir natrium - Google Patents

Lenacapavir of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder lenacapavir natrium

Info

Publication number: NL301212I2
Authority: NL; Netherlands
Prior art keywords: lenacapavir; sodium; pharmaceutically acceptable; acceptable salt; salt
Prior art date: 2016-08-19

Application number

NL301212C

Other languages

English (en)

Other versions

NL301212I1 (nl

Original Assignee

Gilead Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-08-19

Filing date

2023-01-11

Publication date

2023-04-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59714166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL301212(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2023-01-11 Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc

2023-01-12 Publication of NL301212I1 publication Critical patent/NL301212I1/nl

2023-04-06 Publication of NL301212I2 publication Critical patent/NL301212I2/nl

Links

BRYXUCLEHAUSDY-WEWMWRJBSA-N N-[(1S)-1-[3-[4-chloro-3-(methanesulfonamido)-1-(2,2,2-trifluoroethyl)indazol-7-yl]-6-(3-methyl-3-methylsulfonylbut-1-ynyl)pyridin-2-yl]-2-(3,5-difluorophenyl)ethyl]-2-[(2S,4R)-5,5-difluoro-9-(trifluoromethyl)-7,8-diazatricyclo[4.3.0.02,4]nona-1(6),8-dien-7-yl]acetamide Chemical compound O=S(=O)(C(C)(C)C#CC1=NC(=C(C2=CC=C(Cl)C=3C(NS(=O)(=O)C)=NN(CC(F)(F)F)C2=3)C=C1)[C@@H](NC(=O)CN1N=C(C=2[C@@H]3[C@H](C(C1=2)(F)F)C3)C(F)(F)F)CC1=CC(F)=CC(F)=C1)C BRYXUCLEHAUSDY-WEWMWRJBSA-N 0.000 title 1
229940013987 lenacapavir Drugs 0.000 title 1
150000003839 salts Chemical class 0.000 title 1
SSXPGMNGIORJAQ-PZNXWHLTSA-M sodium [4-chloro-7-[2-[(1S)-2-(3,5-difluorophenyl)-1-[[2-[(2S,4R)-5,5-difluoro-9-(trifluoromethyl)-7,8-diazatricyclo[4.3.0.02,4]nona-1(6),8-dien-7-yl]acetyl]amino]ethyl]-6-(3-methyl-3-methylsulfonylbut-1-ynyl)pyridin-3-yl]-1-(2,2,2-trifluoroethyl)indazol-3-yl]-methylsulfonylazanide Chemical compound ClC1=C2C(=NN(C2=C(C=C1)C=1C(=NC(=CC=1)C#CC(C)(S(=O)(=O)C)C)[C@H](CC1=CC(=CC(=C1)F)F)NC(CN1N=C(C2=C1C([C@H]1[C@@H]2C1)(F)F)C(F)(F)F)=O)CC(F)(F)F)[N-]S(=O)(=O)C.[Na+] SSXPGMNGIORJAQ-PZNXWHLTSA-M 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
- C07C317/08—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Virology (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)
Inorganic Chemistry (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Dermatology (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Oil, Petroleum & Natural Gas (AREA)
Engineering & Computer Science (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

NL301212C 2016-08-19 2023-01-11 Lenacapavir of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder lenacapavir natrium NL301212I2 (nl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201662377312P	2016-08-19	2016-08-19
US201762457555P	2017-02-10	2017-02-10
PCT/US2017/047416 WO2018035359A1 (en)	2016-08-19	2017-08-17	Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection

Publications (2)

Publication Number	Publication Date
NL301212I1 NL301212I1 (nl)	2023-01-12
NL301212I2 true NL301212I2 (nl)	2023-04-06

Family

ID=59714166

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL301212C NL301212I2 (nl)	2016-08-19	2023-01-11	Lenacapavir of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder lenacapavir natrium

Country Status (42)

Country	Link
US (4)	US10071985B2 (nl)
EP (3)	EP3347352B1 (nl)
JP (5)	JP6716785B2 (nl)
KR (4)	KR20200131351A (nl)
CN (3)	CN111793061B (nl)
AU (4)	AU2017312102B2 (nl)
BR (2)	BR122020001791B1 (nl)
CA (1)	CA3021227C (nl)
CL (1)	CL2019000415A1 (nl)
CO (1)	CO2019001379A2 (nl)
CR (1)	CR20190084A (nl)
CY (2)	CY1122296T1 (nl)
DK (2)	DK3347352T3 (nl)
DO (1)	DOP2019000033A (nl)
EC (1)	ECSP19011209A (nl)
ES (2)	ES2954514T3 (nl)
FI (1)	FI3597646T3 (nl)
FR (1)	FR22C1063I2 (nl)
HK (1)	HK1256904B (nl)
HR (1)	HRP20231018T1 (nl)
HU (3)	HUE045137T2 (nl)
IL (1)	IL264644B (nl)
JO (1)	JOP20180123A1 (nl)
LT (3)	LT3597646T (nl)
MA (2)	MA42795B1 (nl)
MX (1)	MX369307B (nl)
MY (1)	MY191466A (nl)
NL (1)	NL301212I2 (nl)
NO (1)	NO2022059I1 (nl)
NZ (1)	NZ750706A (nl)
PE (2)	PE20190910A1 (nl)
PH (2)	PH12021552802A1 (nl)
PL (2)	PL3347352T3 (nl)
PT (2)	PT3347352T (nl)
SA (1)	SA519401123B1 (nl)
SG (2)	SG11201808944QA (nl)
SI (2)	SI3597646T1 (nl)
TW (4)	TWI664966B (nl)
UA (1)	UA121630C2 (nl)
UY (1)	UY37367A (nl)
WO (1)	WO2018035359A1 (nl)
ZA (1)	ZA201901430B (nl)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2729448E (pt)	2011-07-06	2015-12-02	Gilead Sciences Inc	Compostos para o tratamento de vih
US10202353B2 (en)	2014-02-28	2019-02-12	Gilead Sciences, Inc.	Therapeutic compounds
PT3347352T (pt)	2016-08-19	2019-09-24	Gilead Sciences Inc	Compostos terapêuticos úteis para o tratamento profilático ou terapêutico de uma infeção pelo vírus hiv
AR112412A1 (es)	2017-08-17	2019-10-23	Gilead Sciences Inc	Formas de sal de colina de un inhibidor de la cápside del vih
TW202024061A (zh) *	2017-08-17	2020-07-01	美商基利科學股份有限公司	Hiv蛋白質膜抑制劑之固體形式
WO2019161017A1 (en)	2018-02-15	2019-08-22	Gilead Sciences, Inc.	Pyridine derivatives and their use for treating hiv infection
AU2019222559B2 (en)	2018-02-16	2022-01-20	Gilead Sciences, Inc.	Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
US20210115061A1 (en) *	2018-06-21	2021-04-22	Drexel University	Small-Molecule HIV-1 Capsid Protein Inhibitors and Methods Using Same
AU2019307500B2 (en) *	2018-07-16	2022-09-29	Gilead Sciences, Inc.	Capsid inhibitors for the treatment of HIV
EP3833436A1 (en) *	2018-08-09	2021-06-16	VIIV Healthcare UK (No.5) Limited	Inhibitors of human immunodeficiency virus replication
US20220089598A1 (en)	2018-09-14	2022-03-24	Viiv Healthcare Uk (No. 5) Limited	Inhibitors of human immunodeficiency virus replication
EP3853228A1 (en)	2018-09-20	2021-07-28	VIIV Healthcare UK (No.5) Limited	Inhibitors of human immunodeficiency virus replication
EP3870576B1 (en)	2018-10-24	2024-01-24	VIIV Healthcare UK (No.5) Limited	Bezopyrazole derivatives as inhibitors of human immunodeficiency virus replication
MX2021004593A (es)	2018-10-24	2021-06-15	Viiv Healthcare Uk No 5 Ltd	Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
PT3870575T (pt)	2018-10-25	2023-05-12	Viiv Healthcare Uk No 5 Ltd	Inibidores da replicação do vírus da imunodeficiência humana
EP3873607B1 (en) *	2018-10-29	2023-11-29	VIIV Healthcare UK (No.5) Limited	Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication
WO2020095177A1 (en) *	2018-11-05	2020-05-14	VIIV Healthcare UK (No.5) Limited	Inhibitors of human immunodeficiency virus replication
JP2022506399A (ja)	2018-11-05	2022-01-17	ヴィーブヘルスケアユーケー（ナンバー５）リミテッド	ヒト免疫不全ウイルス複製の阻害剤
AU2020211600A1 (en)	2019-01-25	2021-07-22	Brown University	Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
UY38559A (es)	2019-02-01	2020-07-31	Viiv Healthcare Uk No 5 Ltd	Inhibidores de la replicación del virus de la inmunodeficiencia humana
KR20240151256A (ko)	2019-03-22	2024-10-17	길리애드 사이언시즈, 인코포레이티드	가교된 트리시클릭 카르바모일피리돈 화합물 및 그의 제약 용도
JP7545414B2 (ja)	2019-04-30	2024-09-04	ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド	ヒト免疫不全ウイルス複製阻害剤
RU2717101C1 (ru)	2019-06-03	2020-03-18	Андрей Александрович Иващенко	Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
BR112021025655A2 (pt) *	2019-06-19	2022-02-01	Viiv Healthcare Uk No 5 Ltd	Inibidores da replicação do vírus da imunodeficiência humana
ES2974657T3 (es)	2019-10-01	2024-07-01	Viiv Healthcare Uk No 5 Ltd	Derivados de n-substituido-6-oxo-1,6-dihidropirimidina-2-ilo como inhibidores de la replicación del virus de inmunodeficiencia humana
JP2022551254A (ja)	2019-10-01	2022-12-08	ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッド	ヒト免疫不全ウイルスの複製阻害剤
TW202128648A (zh)	2019-10-04	2021-08-01	英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司	人類免疫不全病毒複製之抑制劑
WO2021070054A1 (en)	2019-10-08	2021-04-15	VIIV Healthcare UK (No.5) Limited	Inhibitors of human immunodeficiency virus replication
EP4065116A1 (en) *	2019-11-26	2022-10-05	Gilead Sciences, Inc.	Capsid inhibitors for the prevention of hiv
TW202133858A (zh)	2019-11-28	2021-09-16	日商鹽野義製藥股份有限公司	以組合整合酶阻礙劑及抗ｈｉｖ藥為特徵之ｈｉｖ感染症的預防及治療用醫藥
BR112022010204A2 (pt) *	2019-11-29	2022-09-06	Jiangsu Hengrui Medicine Co	Derivado do anel de piridina fusionado, método de preparação para o mesmo e uso farmacêutico do mesmo
CN116098917A (zh) *	2020-02-27	2023-05-12	河南真实生物科技有限公司	核苷类化合物在治疗冠状病毒感染性疾病中的用途
BR112022017832A2 (pt)	2020-03-06	2022-11-01	Viiv Healthcare Uk No 5 Ltd	Inibidores de replicação do vírus da imunodeficiência humana
WO2021176367A1 (en)	2020-03-06	2021-09-10	VIIV Healthcare UK (No.5) Limited	Inhibitors of human immunodeficiency virus replication
CN115605493A (zh)	2020-03-20	2023-01-13	吉利德科学公司（Us）	4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法
US20230149408A1 (en)	2020-04-15	2023-05-18	Viiv Healthcare Uk (No. 5) Limited	Inhibitors of human immunodeficiency virus replication
WO2021236944A1 (en)	2020-05-21	2021-11-25	Gilead Sciences, Inc.	Pharmaceutical compositions comprising bictegravir
WO2021262990A1 (en) *	2020-06-25	2021-12-30	Gilead Sciences, Inc.	Capsid inhibitors for the treatment of hiv
TW202406932A (zh)	2020-10-22	2024-02-16	美商基利科學股份有限公司	介白素2-Fc融合蛋白及使用方法
CA3195799A1 (en)	2020-11-11	2022-05-19	Stephen R. Martin	Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies
AU2022211056A1 (en)	2021-01-25	2023-07-20	Brii Biosciences, Inc.	Combination therapy for hiv with adenosine derivative and capsid inhibitors
TW202313584A (zh) *	2021-05-28	2023-04-01	大陸商江蘇恒瑞醫藥股份有限公司	稠合吡啶環衍生物的可藥用鹽、晶型及其製備方法
KR20230019059A (ko)	2021-07-30	2023-02-07	(주) 에빅스젠	연전초 추출물을 유효성분으로 포함하는, 바이러스성 질환 완화 및 개선용 조성물
KR20230018690A (ko)	2021-07-30	2023-02-07	(주) 에빅스젠	둥근이질풀 추출물을 유효성분으로 포함하는, 바이러스성 질환 치료 및 개선용 조성물
WO2023102523A1 (en)	2021-12-03	2023-06-08	Gilead Sciences, Inc.	Therapeutic compounds for hiv virus infection
CA3235937A1 (en)	2021-12-03	2023-06-08	Gilead Sciences, Inc.	Therapeutic compounds for hiv virus infection
AU2022399845A1 (en)	2021-12-03	2024-05-23	Gilead Sciences, Inc.	Therapeutic compounds for hiv virus infection
TW202446773A (zh)	2022-04-06	2024-12-01	美商基利科學股份有限公司	橋聯三環胺甲醯基吡啶酮化合物及其用途
US20240034724A1 (en) *	2022-07-01	2024-02-01	Gilead Sciences, Inc.	Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
AU2023330037A1 (en)	2022-08-26	2025-03-06	Gilead Sciences, Inc.	Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024076915A1 (en)	2022-10-04	2024-04-11	Gilead Sciences, Inc.	4'-thionucleoside analogues and their pharmaceutical use
KR20240061218A (ko)	2022-10-31	2024-05-08	주식회사 이보드	복합 단열재 및 제조방법
US20240287124A1 (en)	2023-01-30	2024-08-29	Merck Sharp & Dohme Llc	Prodrugs of 4'-substituted nucleoside reverse transcriptase inhibitors
US20240390349A1 (en)	2023-04-19	2024-11-28	Gilead Sciences, Inc.	Dosing regimen of capsid inhibitor
WO2024249672A1 (en)	2023-05-31	2024-12-05	Gilead Sciences, Inc.	Process of preparing hiv capsid inhibitor
US20250042926A1 (en)	2023-05-31	2025-02-06	Gilead Sciences, Inc.	Therapeutic compounds for hiv
US20250011352A1 (en)	2023-05-31	2025-01-09	Gilead Sciences, Inc.	Solid forms
CN116675675A (zh) *	2023-06-05	2023-09-01	北京康立生医药技术开发有限公司	一种艾滋病治疗药物来那卡帕韦中间体化合物的制备方法
WO2024257009A1 (en)	2023-06-15	2024-12-19	VIIV Healthcare UK (No.5) Limited	Methods and intermediates for preparing compounds
WO2025029247A1 (en)	2023-07-28	2025-02-06	Gilead Sciences, Inc.	Weekly regimen of lenacapavir for the treatment and prevention of hiv
US20250073172A1 (en)	2023-08-15	2025-03-06	Gilead Sciences, Inc.	Pharmaceutical formulations of bictegravir and lenacapavir
WO2025042394A1 (en)	2023-08-23	2025-02-27	Gilead Sciences, Inc.	Dosing regimen of hiv capsid inhibitor

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816570A (en)	1982-11-30	1989-03-28	The Board Of Regents Of The University Of Texas System	Biologically reversible phosphate and phosphonate protective groups
US4968788A (en)	1986-04-04	1990-11-06	Board Of Regents, The University Of Texas System	Biologically reversible phosphate and phosphonate protective gruops
DE69115694T2 (de)	1990-06-13	1996-10-17	Arnold Newton Mass. Glazier	Phosphorylierte prodrugs
EP0481214B1 (en)	1990-09-14	1998-06-24	Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic	Prodrugs of phosphonates
US5922695A (en)	1996-07-26	1999-07-13	Gilead Sciences, Inc.	Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5935946A (en)	1997-07-25	1999-08-10	Gilead Sciences, Inc.	Nucleotide analog composition and synthesis method
IL153658A0 (en)	2000-07-21	2003-07-06	Gilead Sciences Inc	Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
ATE370943T1 (de)	2001-06-27	2007-09-15	Smithkline Beecham Corp	Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren
EP1399420B1 (en)	2001-06-27	2007-12-05	SmithKline Beecham Corporation	Pyrrolidines as dipeptidyl peptidase inhibitors
WO2003035076A1 (en)	2001-10-26	2003-05-01	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa	Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
US7642277B2 (en)	2002-12-04	2010-01-05	Boehringer Ingelheim International Gmbh	Non-nucleoside reverse transcriptase inhibitors
WO2004071448A2 (en)	2003-02-12	2004-08-26	Transtech Pharma Inc.	Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
EP1628685B1 (en)	2003-04-25	2010-12-08	Gilead Sciences, Inc.	Antiviral phosphonate analogs
ATE434621T1 (de)	2004-02-27	2009-07-15	Schering Corp	Neue verbindungen als inhibitoren der ns3- serinprotease des hepatitis-c-virus
US7453002B2 (en)	2004-06-15	2008-11-18	Bristol-Myers Squibb Company	Five-membered heterocycles useful as serine protease inhibitors
US7429604B2 (en)	2004-06-15	2008-09-30	Bristol Myers Squibb Company	Six-membered heterocycles useful as serine protease inhibitors
CN101027062A (zh)	2004-07-27	2007-08-29	吉里德科学公司	Hiv抑制剂化合物的膦酸酯类似物
US8067587B2 (en)	2005-07-28	2011-11-29	Lenroc Company	Process for the production of monoalkali metal cyanurates
JP2009503069A (ja)	2005-08-05	2009-01-29	アストラゼネカアクチボラグ	三環式ベンゾイミダゾール類、および代謝性グルタミン酸塩受容体のモジュレータとしてのそれらの使用
ATE511502T1 (de)	2005-12-14	2011-06-15	Bristol Myers Squibb Co	Arylpropionamid-, arylacrylamid-, arylpropinamid- oder arylmethylharnstoffanaloge als faktor-xia- inhibitoren
CA2648569C (en)	2006-04-12	2012-02-07	Merck & Co., Inc.	Pyridyl amide t-type calcium channel antagonists
US7647464B2 (en)	2006-04-28	2010-01-12	At&T Intellectual Property, I,L.P.	Methods, systems, and products for recording media to a restoration server
WO2008013622A2 (en)	2006-07-27	2008-01-31	E. I. Du Pont De Nemours And Company	Fungicidal azocyclic amides
US8124811B2 (en)	2007-03-20	2012-02-28	Allylix, Inc.	Fragrance and methods for production of 5-epi-β-vetivone, 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-2,6-dien-8-one, and 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-1,6-dien-8-one
CN101702908A (zh)	2007-03-23	2010-05-05	麻萨诸塞州大学	Hiv-1蛋白酶抑制剂
EP2162432A2 (en)	2007-06-29	2010-03-17	Gilead Sciences, Inc.	Antiviral compounds
EP2175857B1 (en)	2007-07-12	2013-09-11	Janssen R&D Ireland	Crystalline form of (e) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US8927569B2 (en)	2007-07-19	2015-01-06	Merck Sharp & Dohme Corp.	Macrocyclic compounds as antiviral agents
JP5524071B2 (ja)	2007-10-24	2014-06-18	メルク・シャープ・アンド・ドーム・コーポレーション	複素環フェニルアミドｔ型カルシウムチャネルアンタゴニスト
JP2011500808A (ja)	2007-10-24	2011-01-06	メルク・シャープ・エンド・ドーム・コーポレイション	複素環アミドｔ型カルシウムチャネルアンタゴニスト
MX2010005334A (es)	2007-11-16	2010-05-27	Boehringer Ingelheim Int	Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
US8324199B2 (en)	2008-03-13	2012-12-04	Bristol-Myers Squibb Company	Pyridazine derivatives as factor xia inhibitors
AU2009333559B2 (en)	2008-12-09	2015-03-12	Gilead Sciences, Inc.	Modulators of toll-like receptors
CN102414217A (zh)	2009-02-25	2012-04-11	彼格泰格私人有限公司	用于检测基孔肯雅病毒的探针和引物
US8338441B2 (en)	2009-05-15	2012-12-25	Gilead Sciences, Inc.	Inhibitors of human immunodeficiency virus replication
US20110274648A1 (en)	2009-11-11	2011-11-10	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
WO2011094890A1 (en)	2010-02-02	2011-08-11	Argusina Inc.	Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
WO2011139637A1 (en)	2010-05-03	2011-11-10	Philadelphia Health & Education Corporation	Small-molecule modulators of hiv-1 capsid stability and methods thereof
WO2011143772A1 (en)	2010-05-21	2011-11-24	Boehringer Ingelheim International Gmbh	Inhibitors of hiv replication
US9296758B2 (en)	2010-07-02	2016-03-29	Gilead Sciences, Inc.	2-quinolinyl-acetic acid derivatives as HIV antiviral compounds
KR20130135826A (ko)	2010-07-02	2013-12-11	길리애드 사이언시즈, 인코포레이티드	Ａｉｄｓ를 치료하기 위한 나프트-2-일아세트산 유도체
CN102464654B (zh)	2010-11-12	2016-01-13	上海泓博智源医药技术有限公司	抗病毒化合物
CA2830742C (en)	2011-03-23	2023-03-14	Trevena, Inc.	Substituted oxanes as opioid receptor ligands and methods of using and making same
EP2699558B1 (en)	2011-04-21	2016-11-23	Gilead Sciences, Inc.	Benzothiazole compounds and their pharmaceutical use
PT2729448E (pt)	2011-07-06	2015-12-02	Gilead Sciences Inc	Compostos para o tratamento de vih
CN102863512B (zh)	2011-07-07	2016-04-20	上海泓博智源医药技术有限公司	抗病毒化合物
CA2845553C (en)	2011-08-16	2019-05-28	Gilead Sciences, Inc.	Tenofovir alafenamide hemifumarate
US9399645B2 (en)	2011-12-20	2016-07-26	Boehringer Ingelheim International Gmbh	Inhibitors of HIV replication
PE20141558A1 (es)	2012-04-20	2014-11-06	Gilead Sciences Inc	Derivados de acido benzotiazol-6-il acetico y su uso para tratar una infeccion por vih
GB201213087D0 (en)	2012-07-24	2012-09-05	Medical Res Council	Inhibition of HIV-1 infection
US9447134B2 (en)	2012-08-17	2016-09-20	Brandeis University	Compounds and methods for treating mammalian gastrointestinal microbial infections
KR20230061576A (ko)	2012-12-21	2023-05-08	길리애드 사이언시즈, 인코포레이티드	폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
JP6320039B2 (ja)	2012-12-27	2018-05-09	日本たばこ産業株式会社	置換されたスピロピリド［１，２−ａ］ピラジン誘導体及びそのＨＩＶインテグラーゼ阻害剤としての医薬用途
TW201443037A (zh) *	2013-01-09	2014-11-16	Gilead Sciences Inc	治療用化合物
JP5941598B2 (ja)	2013-01-09	2016-06-29	ギリアードサイエンシーズ，インコーポレイテッド	５員ヘテロアリールおよびそれらの抗ウイルス剤としての使用
PL2943493T3 (pl)	2013-01-09	2017-12-29	Gilead Sciences, Inc.	Związki terapeutyczne do leczenia zakażeń wirusowych
EP2769722A1 (en)	2013-02-22	2014-08-27	Ruprecht-Karls-Universität Heidelberg	Compounds for use in inhibiting HIV capsid assembly
US20140296266A1 (en)	2013-03-01	2014-10-02	Gilead Sciences, Inc.	Therapeutic compounds
TWI706945B (zh) *	2013-03-01	2020-10-11	美商基利科學股份有限公司	供治療反轉錄病毒科病毒感染之治療性化合物
GB201312991D0 (en)	2013-07-19	2013-09-04	Isis Innovation	Process
JP6466433B2 (ja)	2013-10-24	2019-02-06	ビーブ・ヘルスケア・ユーケイ・（ナンバー５）・リミテッドＶｉｉＶＨｅａｌｔｈｃａｒｅＵＫ（Ｎｏ．５）Ｌｉｍｉｔｅｄ	ヒト免疫不全ウイルス複製の阻害剤
WO2015130966A1 (en)	2014-02-28	2015-09-03	Gilead Sciences, Inc.	Antiviral agents
US10202353B2 (en)	2014-02-28	2019-02-12	Gilead Sciences, Inc.	Therapeutic compounds
ES2695700T3 (es) *	2014-08-29	2019-01-10	Gilead Sciences Inc	Agentes antirretrovirales
WO2016040084A1 (en)	2014-09-09	2016-03-17	Bristol-Myers Squibb Company	Inhibitors of human immunodeficiency virus replication
MX2017008520A (es)	2014-12-24	2018-03-01	Gilead Sciences Inc	Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih).
TW202237569A (zh)	2014-12-24	2022-10-01	美商基利科學股份有限公司	喹唑啉化合物
KR20180005195A (ko)	2015-04-23	2018-01-15	비브 헬스케어 유케이 (넘버5) 리미티드	인간 면역결핍 바이러스 복제의 억제제
PT3286166T (pt)	2015-04-23	2020-08-18	Viiv Healthcare Uk No 5 Ltd	Inibidores de replicação do vírus da imunodeficiência humana
HUE043310T2 (hu) *	2015-07-06	2019-08-28	Gilead Sciences Inc	COT modulátorok és eljárások alkalmazásukra
US10171985B1 (en)	2015-07-22	2019-01-01	Ginko LLC	Method and apparatus for data sharing
PT3347352T (pt)	2016-08-19	2019-09-24	Gilead Sciences Inc	Compostos terapêuticos úteis para o tratamento profilático ou terapêutico de uma infeção pelo vírus hiv
JOP20180009A1 (ar)	2017-02-06	2019-01-30	Gilead Sciences Inc	مركبات مثبط فيروس hiv
TW201906834A (zh)	2017-05-02	2019-02-16	英商Viiv醫療保健英國(No.5)有限公司	人類免疫不全病毒複製之抑制劑
AR112412A1 (es)	2017-08-17	2019-10-23	Gilead Sciences Inc	Formas de sal de colina de un inhibidor de la cápside del vih
TW202024061A (zh)	2017-08-17	2020-07-01	美商基利科學股份有限公司	Hiv蛋白質膜抑制劑之固體形式
WO2019161017A1 (en)	2018-02-15	2019-08-22	Gilead Sciences, Inc.	Pyridine derivatives and their use for treating hiv infection
AU2019222559B2 (en)	2018-02-16	2022-01-20	Gilead Sciences, Inc.	Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
US10911396B2 (en)	2018-06-28	2021-02-02	Paypal, Inc.	Mid-tier messaging system
AU2019307500B2 (en)	2018-07-16	2022-09-29	Gilead Sciences, Inc.	Capsid inhibitors for the treatment of HIV
EP4065116A1 (en)	2019-11-26	2022-10-05	Gilead Sciences, Inc.	Capsid inhibitors for the prevention of hiv
WO2021262990A1 (en)	2020-06-25	2021-12-30	Gilead Sciences, Inc.	Capsid inhibitors for the treatment of hiv

2017
- 2017-08-17 PT PT17758388T patent/PT3347352T/pt unknown
- 2017-08-17 KR KR1020207032788A patent/KR20200131351A/ko not_active Application Discontinuation
- 2017-08-17 DK DK17758388.7T patent/DK3347352T3/da active
- 2017-08-17 CN CN202010662665.4A patent/CN111793061B/zh active Active
- 2017-08-17 FI FIEP19178148.3T patent/FI3597646T3/fi active
- 2017-08-17 PT PT191781483T patent/PT3597646T/pt unknown
- 2017-08-17 LT LTEP19178148.3T patent/LT3597646T/lt unknown
- 2017-08-17 BR BR122020001791-0A patent/BR122020001791B1/pt active IP Right Grant
- 2017-08-17 LT LTEP17758388.7T patent/LT3347352T/lt unknown
- 2017-08-17 SI SI201731404T patent/SI3597646T1/sl unknown
- 2017-08-17 UY UY0001037367A patent/UY37367A/es not_active Application Discontinuation
- 2017-08-17 KR KR1020247014103A patent/KR20240070646A/ko active Pending
- 2017-08-17 CA CA3021227A patent/CA3021227C/en active Active
- 2017-08-17 MX MX2018012905A patent/MX369307B/es active IP Right Grant
- 2017-08-17 WO PCT/US2017/047416 patent/WO2018035359A1/en active Application Filing
- 2017-08-17 PE PE2019000375A patent/PE20190910A1/es unknown
- 2017-08-17 ES ES19178148T patent/ES2954514T3/es active Active
- 2017-08-17 DK DK19178148.3T patent/DK3597646T3/da active
- 2017-08-17 TW TW106127987A patent/TWI664966B/zh active
- 2017-08-17 MA MA42795A patent/MA42795B1/fr unknown
- 2017-08-17 PH PH1/2021/552802A patent/PH12021552802A1/en unknown
- 2017-08-17 TW TW112100805A patent/TWI853404B/zh active
- 2017-08-17 MA MA050673A patent/MA50673A/fr unknown
- 2017-08-17 UA UAA201901739 patent/UA121630C2/uk unknown
- 2017-08-17 US US15/680,041 patent/US10071985B2/en active Active
- 2017-08-17 SG SG11201808944QA patent/SG11201808944QA/en unknown
- 2017-08-17 CN CN201780063636.2A patent/CN109890808B/zh active Active
- 2017-08-17 SG SG10201912535VA patent/SG10201912535VA/en unknown
- 2017-08-17 KR KR1020237000165A patent/KR20230011471A/ko not_active Ceased
- 2017-08-17 PL PL17758388T patent/PL3347352T3/pl unknown
- 2017-08-17 TW TW108108262A patent/TWI715944B/zh active
- 2017-08-17 CN CN202411603090.3A patent/CN119462611A/zh active Pending
- 2017-08-17 AU AU2017312102A patent/AU2017312102B2/en active Active
- 2017-08-17 TW TW109146483A patent/TW202138365A/zh unknown
- 2017-08-17 BR BR112018071678-2A patent/BR112018071678B1/pt active Search and Examination
- 2017-08-17 PL PL19178148.3T patent/PL3597646T3/pl unknown
- 2017-08-17 CR CR20190084A patent/CR20190084A/es unknown
- 2017-08-17 MY MYPI2019000877A patent/MY191466A/en unknown
- 2017-08-17 HU HUE17758388A patent/HUE045137T2/hu unknown
- 2017-08-17 ES ES17758388T patent/ES2746374T3/es active Active
- 2017-08-17 NZ NZ750706A patent/NZ750706A/en unknown
- 2017-08-17 EP EP17758388.7A patent/EP3347352B1/en active Active
- 2017-08-17 JP JP2019508953A patent/JP6716785B2/ja active Active
- 2017-08-17 HU HUE19178148A patent/HUE063811T2/hu unknown
- 2017-08-17 PE PE2020000548A patent/PE20211427A1/es unknown
- 2017-08-17 EP EP23179840.6A patent/EP4265299A3/en active Pending
- 2017-08-17 SI SI201730077T patent/SI3347352T1/sl unknown
- 2017-08-17 HR HRP20231018TT patent/HRP20231018T1/hr unknown
- 2017-08-17 KR KR1020197007456A patent/KR102180740B1/ko active IP Right Grant
- 2017-08-17 EP EP19178148.3A patent/EP3597646B1/en active Active
2018
- 2018-06-25 US US16/016,718 patent/US10654827B2/en active Active
- 2018-12-13 HK HK18116015.7A patent/HK1256904B/zh unknown
- 2018-12-16 JO JOP/2018/0123A patent/JOP20180123A1/ar unknown
2019
- 2019-02-04 IL IL264644A patent/IL264644B/en active IP Right Grant
- 2019-02-15 EC ECSENADI201911209A patent/ECSP19011209A/es unknown
- 2019-02-15 PH PH12019500335A patent/PH12019500335A1/en unknown
- 2019-02-15 CL CL2019000415A patent/CL2019000415A1/es unknown
- 2019-02-15 DO DO2019000033A patent/DOP2019000033A/es unknown
- 2019-02-15 CO CONC2019/0001379A patent/CO2019001379A2/es unknown
- 2019-02-18 SA SA519401123A patent/SA519401123B1/ar unknown
- 2019-03-07 ZA ZA2019/01430A patent/ZA201901430B/en unknown
- 2019-09-13 CY CY20191100958T patent/CY1122296T1/el unknown
- 2019-11-25 US US16/694,332 patent/US11993583B2/en active Active
2020
- 2020-03-18 JP JP2020048130A patent/JP2020111592A/ja not_active Withdrawn
- 2020-04-02 AU AU2020202331A patent/AU2020202331C1/en active Active
- 2020-10-19 JP JP2020175151A patent/JP2021008516A/ja active Pending
2021
- 2021-08-26 AU AU2021221855A patent/AU2021221855B2/en active Active
2022
- 2022-10-27 JP JP2022172416A patent/JP2023011754A/ja not_active Withdrawn
- 2022-12-14 HU HUS2200053C patent/HUS2200053I1/hu unknown
- 2022-12-16 NO NO2022059C patent/NO2022059I1/no unknown
- 2022-12-16 FR FR22C1063C patent/FR22C1063I2/fr active Active
- 2022-12-22 CY CY2022039C patent/CY2022039I2/el unknown
2023
- 2023-01-05 LT LTPA2023501C patent/LTPA2023501I1/lt unknown
- 2023-01-11 NL NL301212C patent/NL301212I2/nl unknown
- 2023-11-27 AU AU2023271739A patent/AU2023271739A1/en active Pending
2024
- 2024-04-11 US US18/632,593 patent/US20240376077A1/en active Pending
- 2024-08-30 JP JP2024148326A patent/JP2024170471A/ja active Pending

Also Published As

Publication number	Publication date
PL3597646T3 (pl)	2023-12-11
KR20230011471A (ko)	2023-01-20
PE20190910A1 (es)	2019-06-26
HUS2200053I1 (hu)	2023-01-28
TW202138365A (zh)	2021-10-16
PE20211427A1 (es)	2021-08-03
MX369307B (es)	2019-11-05
CN109890808A (zh)	2019-06-14
US10654827B2 (en)	2020-05-19
JP2024170471A (ja)	2024-12-10
TW201922711A (zh)	2019-06-16
CO2019001379A2 (es)	2019-02-19
KR20200131351A (ko)	2020-11-23
US20180051005A1 (en)	2018-02-22
DK3597646T3 (da)	2023-09-04
AU2017312102A1 (en)	2019-03-07
BR122020001791B1 (pt)	2022-01-25
CN111793061A (zh)	2020-10-20
US11993583B2 (en)	2024-05-28
CA3021227A1 (en)	2018-02-22
CN111793061B (zh)	2024-11-26
EP3347352B1 (en)	2019-07-03
JP2019528280A (ja)	2019-10-10
CN109890808B (zh)	2020-08-07
FR22C1063I2 (fr)	2023-12-15
NL301212I1 (nl)	2023-01-12
CR20190084A (es)	2019-05-02
JP6716785B2 (ja)	2020-07-01
US20180370950A1 (en)	2018-12-27
MA42795B1 (fr)	2019-08-30
EP3347352A1 (en)	2018-07-18
CA3021227C (en)	2020-11-03
EP4265299A2 (en)	2023-10-25
CY1122296T1 (el)	2021-01-27
PH12021552802A1 (en)	2022-07-04
TWI853404B (zh)	2024-08-21
EP3597646A1 (en)	2020-01-22
ES2746374T3 (es)	2020-03-05
JP2023011754A (ja)	2023-01-24
SA519401123B1 (ar)	2022-11-09
HRP20231018T1 (hr)	2023-12-08
MY191466A (en)	2022-06-28
JOP20180123A1 (ar)	2019-01-30
EP4265299A3 (en)	2024-01-17
DK3347352T3 (da)	2019-08-26
TWI715944B (zh)	2021-01-11
BR112018071678A2 (pt)	2019-02-19
AU2021221855B2 (en)	2023-08-31
HUE045137T2 (hu)	2019-12-30
SI3347352T1 (sl)	2019-08-30
SG11201808944QA (en)	2018-11-29
TW201811327A (zh)	2018-04-01
CY2022039I1 (el)	2023-01-27
JP2020111592A (ja)	2020-07-27
KR20190039431A (ko)	2019-04-11
KR20240070646A (ko)	2024-05-21
CY2022039I2 (el)	2023-01-27
MA42795A (fr)	2019-07-03
ES2954514T3 (es)	2023-11-22
LTPA2023501I1 (nl)	2023-02-10
MX2018012905A (es)	2019-01-30
US10071985B2 (en)	2018-09-11
UY37367A (es)	2018-03-23
TWI664966B (zh)	2019-07-11
PH12019500335A1 (en)	2019-11-11
SI3597646T1 (sl)	2023-10-30
LT3597646T (lt)	2023-09-25
AU2021221855A1 (en)	2021-09-23
NZ750706A (en)	2020-07-31
BR112018071678B1 (pt)	2021-01-26
AU2020202331A1 (en)	2020-04-23
KR102180740B1 (ko)	2020-11-20
US20200262815A1 (en)	2020-08-20
AU2023271739A1 (en)	2023-12-14
ZA201901430B (en)	2021-09-29
TW202342449A (zh)	2023-11-01
NO2022059I1 (no)	2022-12-16
PL3347352T3 (pl)	2019-12-31
US20240376077A1 (en)	2024-11-14
AU2017312102B2 (en)	2020-03-05
CL2019000415A1 (es)	2019-06-21
FR22C1063I1 (fr)	2023-02-03
HUE063811T2 (hu)	2024-02-28
PT3597646T (pt)	2023-09-11
SG10201912535VA (en)	2020-02-27
ECSP19011209A (es)	2019-02-28
MA50673A (fr)	2020-08-05
CN119462611A (zh)	2025-02-18
EP3597646B1 (en)	2023-06-21
AU2020202331C1 (en)	2021-08-26
IL264644B (en)	2019-09-26
JP2021008516A (ja)	2021-01-28
DOP2019000033A (es)	2019-03-15
HK1256904B (zh)	2020-07-17
UA121630C2 (nl)	2020-06-25
AU2020202331B2 (en)	2021-05-27
WO2018035359A1 (en)	2018-02-22
PT3347352T (pt)	2019-09-24
LT3347352T (lt)	2019-08-12
FI3597646T3 (fi)	2023-09-07

Publication	Publication Date	Title
NL301212I2 (nl)	2023-04-06	Lenacapavir of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder lenacapavir natrium
NL301286I2 (nl)	2024-09-18	Danicopan, of een farmaceutisch aanvaardbaar zout ervan
NL301128I2 (nl)	2021-10-25	Risdiplam of een farmaceutisch aanvaardbaar zout daarvan
NL301111I2 (nl)	2021-09-27	Entrectinib of een farmaceutisch aanvaardbaar zout daarvan
NL301292I2 (nl)	2024-10-30	Iptacopan of een farmaceutisch aanvaardbaar zout daarvan
NL301253I2 (nl)	2024-01-10	mavacamten of een farmaceutisch aanvaardbaar zout daarvan
NO2024001I1 (no)	2024-01-09	Ritlecitinib, or a pharmaceutically acceptable salt thereof
NL301217I2 (nl)	2023-04-04	tirzepatide en farmaceutisch aanvaardbare zouten daarvan
NL301279I2 (nl)	2024-08-01	Adagrasib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NO2022004I1 (no)	2022-02-01	abrocitinib, or a pharmaceutically acceptable salt thereof
NO2022005I1 (no)	2022-02-03	Zanubrutinib or a pharmaceutically acceptable salt thereof
NO2022009I1 (no)	2022-04-05	Lumasiran, optionally in the form of a salt
NO2022046I1 (no)	2022-11-07	Berotralstat and pharmaceutically acceptable salts thereof
NL301224I2 (nl)	2023-08-16	Combinatie van foslevodopa en foscarbidopa, elk desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NO2024007I1 (no)	2024-02-21	Elacestrant or a salt thereof
NO2024009I1 (no)	2024-03-06	Gefapixant, or a pharmaceutically acceptable salt thereof
FIC20240025I1 (fi)	2024-07-12	Momelotinibi, mukaanlukien momelotinibidihydrokloridimonohydraatti
NO2022058I1 (no)	2022-12-16	Capmatinib or a pharmaceutically acceptable salt thereof
DK3188724T3 (da)	2022-02-07	Liposom-indkapslet affinitetsmedikament
NL301061I2 (nl)	2020-10-08	givosiran of een farmaceutisch aanvaardbaar zout daarvan
EP3357054C0 (en)	2023-08-30	HYSTERECTOMY MODEL
BR112017027227A2 (pt)	2018-08-21	Agente anti-câncer
DK3463345T3 (da)	2023-01-09	Farmaceutiske kombinationer
IL255823A (en)	2018-01-31	Urea derivative or pharmacologically acceptable salt thereof
EP3437644A4 (en)	2019-11-27	MEDICINE